BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

459 related articles for article (PubMed ID: 26428461)

  • 1. A stapled peptide antagonist of MDM2 carried by polymeric micelles sensitizes glioblastoma to temozolomide treatment through p53 activation.
    Chen X; Tai L; Gao J; Qian J; Zhang M; Li B; Xie C; Lu L; Lu W; Lu W
    J Control Release; 2015 Nov; 218():29-35. PubMed ID: 26428461
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cyclic RGD conjugated poly(ethylene glycol)-co-poly(lactic acid) micelle enhances paclitaxel anti-glioblastoma effect.
    Zhan C; Gu B; Xie C; Li J; Liu Y; Lu W
    J Control Release; 2010 Apr; 143(1):136-42. PubMed ID: 20056123
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Human glioblastoma multiforme: p53 reactivation by a novel MDM2 inhibitor.
    Costa B; Bendinelli S; Gabelloni P; Da Pozzo E; Daniele S; Scatena F; Vanacore R; Campiglia P; Bertamino A; Gomez-Monterrey I; Sorriento D; Del Giudice C; Iaccarino G; Novellino E; Martini C
    PLoS One; 2013; 8(8):e72281. PubMed ID: 23977270
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combination therapy in a xenograft model of glioblastoma: enhancement of the antitumor activity of temozolomide by an MDM2 antagonist.
    Wang H; Cai S; Bailey BJ; Reza Saadatzadeh M; Ding J; Tonsing-Carter E; Georgiadis TM; Zachary Gunter T; Long EC; Minto RE; Gordon KR; Sen SE; Cai W; Eitel JA; Waning DL; Bringman LR; Wells CD; Murray ME; Sarkaria JN; Gelbert LM; Jones DR; Cohen-Gadol AA; Mayo LD; Shannon HE; Pollok KE
    J Neurosurg; 2017 Feb; 126(2):446-459. PubMed ID: 27177180
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Co-delivery of TRAIL gene enhances the anti-glioblastoma effect of paclitaxel in vitro and in vivo.
    Zhan C; Wei X; Qian J; Feng L; Zhu J; Lu W
    J Control Release; 2012 Jun; 160(3):630-6. PubMed ID: 22410115
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeted Brain Tumor Therapy by Inhibiting the MDM2 Oncogene: In Vitro and In Vivo Antitumor Activity and Mechanism of Action.
    Punganuru SR; Artula V; Zhao W; Rajaei M; Deokar H; Zhang R; Buolamwini JK; Srivenugopal KS; Wang W
    Cells; 2020 Jul; 9(7):. PubMed ID: 32630235
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Decitabine nanoconjugate sensitizes human glioblastoma cells to temozolomide.
    Cui Y; Naz A; Thompson DH; Irudayaraj J
    Mol Pharm; 2015 Apr; 12(4):1279-88. PubMed ID: 25751281
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Temozolomide-loaded photopolymerizable PEG-DMA-based hydrogel for the treatment of glioblastoma.
    Fourniols T; Randolph LD; Staub A; Vanvarenberg K; Leprince JG; Préat V; des Rieux A; Danhier F
    J Control Release; 2015 Jul; 210():95-104. PubMed ID: 25982679
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficient delivery of docetaxel for the treatment of brain tumors by cyclic RGD-tagged polymeric micelles.
    Li AJ; Zheng YH; Liu GD; Liu WS; Cao PC; Bu ZF
    Mol Med Rep; 2015 Apr; 11(4):3078-86. PubMed ID: 25434368
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeted delivery of a novel palmitylated D-peptide for antiglioblastoma molecular therapy.
    Li C; Shen J; Wei X; Xie C; Lu W
    J Drug Target; 2012 Apr; 20(3):264-71. PubMed ID: 22233211
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Novel RGD containing, temozolomide-loading nanostructured lipid carriers for glioblastoma multiforme chemotherapy.
    Song S; Mao G; Du J; Zhu X
    Drug Deliv; 2016 May; 23(4):1404-8. PubMed ID: 26203687
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Integrin αVβ3 silencing sensitizes malignant glioma cells to temozolomide by suppression of homologous recombination repair.
    Christmann M; Diesler K; Majhen D; Steigerwald C; Berte N; Freund H; Stojanović N; Kaina B; Osmak M; Ambriović-Ristov A; Tomicic MT
    Oncotarget; 2017 Apr; 8(17):27754-27771. PubMed ID: 27487141
    [TBL] [Abstract][Full Text] [Related]  

  • 13. cRGD peptide-installed epirubicin-loaded polymeric micelles for effective targeted therapy against brain tumors.
    Quader S; Liu X; Chen Y; Mi P; Chida T; Ishii T; Miura Y; Nishiyama N; Cabral H; Kataoka K
    J Control Release; 2017 Jul; 258():56-66. PubMed ID: 28483513
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CXCR4 antagonism sensitizes cancer cells to novel indole-based MDM2/4 inhibitors in glioblastoma multiforme.
    Daniele S; La Pietra V; Piccarducci R; Pietrobono D; Cavallini C; D'Amore VM; Cerofolini L; Giuntini S; Russomanno P; Puxeddu M; Nalli M; Pedrini M; Fragai M; Luchinat C; Novellino E; Taliani S; La Regina G; Silvestri R; Martini C; Marinelli L
    Eur J Pharmacol; 2021 Apr; 897():173936. PubMed ID: 33581134
    [TBL] [Abstract][Full Text] [Related]  

  • 15. D-peptide inhibitors of the p53-MDM2 interaction for targeted molecular therapy of malignant neoplasms.
    Liu M; Li C; Pazgier M; Li C; Mao Y; Lv Y; Gu B; Wei G; Yuan W; Zhan C; Lu WY; Lu W
    Proc Natl Acad Sci U S A; 2010 Aug; 107(32):14321-6. PubMed ID: 20660730
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Delivery of a drug cache to glioma cells overexpressing platelet-derived growth factor receptor using lipid nanocarriers.
    Miller K; Dixit S; Bredlau AL; Moore A; McKinnon E; Broome AM
    Nanomedicine (Lond); 2016 Mar; 11(6):581-95. PubMed ID: 27003178
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Anticancer drug candidate CBL0137, which inhibits histone chaperone FACT, is efficacious in preclinical orthotopic models of temozolomide-responsive and -resistant glioblastoma.
    Barone TA; Burkhart CA; Safina A; Haderski G; Gurova KV; Purmal AA; Gudkov AV; Plunkett RJ
    Neuro Oncol; 2017 Feb; 19(2):186-196. PubMed ID: 27370399
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combined inhibition of AKT/mTOR and MDM2 enhances Glioblastoma Multiforme cell apoptosis and differentiation of cancer stem cells.
    Daniele S; Costa B; Zappelli E; Da Pozzo E; Sestito S; Nesi G; Campiglia P; Marinelli L; Novellino E; Rapposelli S; Martini C
    Sci Rep; 2015 Apr; 5():9956. PubMed ID: 25898313
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Study on Therapeutic Action and Mechanism of TMZ Combined with RITA Against Glioblastoma.
    Wu Q; Cao Z; Xiao W; Zhu L; Xie Q; Li L; Zhang B; Zhao W
    Cell Physiol Biochem; 2018; 51(6):2536-2546. PubMed ID: 30562758
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Integrin α5β1 plays a critical role in resistance to temozolomide by interfering with the p53 pathway in high-grade glioma.
    Janouskova H; Maglott A; Leger DY; Bossert C; Noulet F; Guerin E; Guenot D; Pinel S; Chastagner P; Plenat F; Entz-Werle N; Lehmann-Che J; Godet J; Martin S; Teisinger J; Dontenwill M
    Cancer Res; 2012 Jul; 72(14):3463-70. PubMed ID: 22593187
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.